Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Jan 04, 2018 13:45 pm UTC| Business
MORRIS PLAINS, N.J., Jan. 04, 2018 -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer, will present an overview of the Company...
DryShips Inc. Announces Successful Delivery of Its Fourth Very Large Gas Carrier
Jan 04, 2018 13:45 pm UTC| Business
ATHENS, Greece, Jan. 04, 2018 -- DryShips Inc. (NASDAQ:DRYS) (“DryShips” or the “Company”), a diversified owner of ocean going cargo vessels, announced today that it has taken delivery of its fourth high specification...
Jan 04, 2018 13:42 pm UTC| Business
WASHINGTON, N.J., Jan. 04, 2018 -- The global graphite electrodes market was valued at $5.04 billion in 2016, and is projected to reach $27.5 billion by 2022, growing at a CAGR of 28.4% from 2017 to 2024. In 2016, the...
Ultragenyx to Present at J.P. Morgan Healthcare Conference
Jan 04, 2018 13:35 pm UTC| Business
NOVATO, Calif., Jan. 04, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D....
Noble Energy to Host Conference Call and Webcast on February 20
Jan 04, 2018 13:33 pm UTC| Business
Houston, Jan. 04, 2018 -- Noble Energy, Inc. (NYSE: NBL) (“Noble Energy” or “the Company”) will host a conference call and webcast for investors and analysts beginning at 8:00 a.m., Central Time, on Tuesday, February...
International Endeavors Excited About California Marijuana Legalization
Jan 04, 2018 13:33 pm UTC| Business
TEMECULA, Calif., Jan. 04, 2018 -- via OTC PR WIRE — International Endeavors Corp (OTC:IDVV) is pleased to announce the following: The arrival of 2018 in California brought with it broad legalization of marijuana, a...
Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
Jan 04, 2018 13:33 pm UTC| Business
SEATTLE, Jan. 04, 2018 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an investigational oral, small molecule...